{"id":"cohort-c-bevacizumab","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Hypertension"},{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"5-20%","effect":"Headache"},{"rate":"5-20%","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to VEGF-A, bevacizumab prevents the formation of new blood vessels, thereby inhibiting tumor growth and metastasis. This mechanism is particularly effective in treating cancers that are highly vascularized.","oneSentence":"Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:27:05.824Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Metastatic non-small cell lung cancer"},{"name":"Metastatic renal cell carcinoma"},{"name":"Epithelial ovarian cancer"},{"name":"Glioblastoma"}]},"trialDetails":[{"nctId":"NCT06703073","phase":"PHASE2","title":"JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)","status":"RECRUITING","sponsor":"PPD Development, LP","startDate":"2025-06-10","conditions":"Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)","enrollment":600},{"nctId":"NCT06701656","phase":"PHASE2","title":"JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab","status":"RECRUITING","sponsor":"PPD Development, LP","startDate":"2025-10-28","conditions":"Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)","enrollment":200},{"nctId":"NCT06233942","phase":"PHASE1","title":"Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2024-04-12","conditions":"Advanced Solid Tumor","enrollment":308},{"nctId":"NCT06011772","phase":"EARLY_PHASE1","title":"EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2023-12-18","conditions":"Colo-rectal Cancer","enrollment":2},{"nctId":"NCT03178552","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-09-22","conditions":"Non-Small Cell Lung Cancer","enrollment":1000},{"nctId":"NCT04449874","phase":"PHASE1","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2020-07-29","conditions":"Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors","enrollment":498},{"nctId":"NCT05238922","phase":"PHASE1","title":"Study of INCB123667 in Subjects With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2022-07-05","conditions":"Solid Tumors","enrollment":604},{"nctId":"NCT04587128","phase":"PHASE2","title":"Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2020-10-19","conditions":"Metastatic Colorectal Cancer","enrollment":34},{"nctId":"NCT03798626","phase":"PHASE1","title":"Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-22","conditions":"Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma","enrollment":167},{"nctId":"NCT05249426","phase":"PHASE1","title":"A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2022-04-12","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":48},{"nctId":"NCT06400472","phase":"PHASE1","title":"A Study of LY4170156 in Participants With Selected Advanced Solid Tumors","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-05-20","conditions":"Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms","enrollment":495},{"nctId":"NCT07233850","phase":"PHASE2","title":"A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers","status":"NOT_YET_RECRUITING","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2025-11","conditions":"Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":300},{"nctId":"NCT03468426","phase":"PHASE1","title":"A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2018-07-05","conditions":"Non-squamous, Non-Small-Cell Lung Cancer, Neoplasms","enrollment":252},{"nctId":"NCT05440708","phase":"PHASE1, PHASE2","title":"A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Tvardi Therapeutics, Incorporated","startDate":"2023-03-23","conditions":"Hepatocellular Carcinoma","enrollment":178},{"nctId":"NCT03520686","phase":"PHASE3","title":"Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-18","conditions":"Non Small Cell Lung Cancer","enrollment":1538},{"nctId":"NCT05609370","phase":"PHASE1, PHASE2","title":"A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2023-01-29","conditions":"Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer","enrollment":113},{"nctId":"NCT05104567","phase":"PHASE2","title":"A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-12-09","conditions":"Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma","enrollment":138},{"nctId":"NCT04607421","phase":"PHASE3","title":"A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-12-21","conditions":"Neoplasms","enrollment":831},{"nctId":"NCT03574779","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2018-11-15","conditions":"Ovarian Neoplasms","enrollment":77},{"nctId":"NCT04121455","phase":"PHASE1, PHASE2","title":"Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"TME Pharma AG","startDate":"2019-09-12","conditions":"Glioblastoma","enrollment":117},{"nctId":"NCT05713994","phase":"","title":"Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Ze-yang Ding, MD","startDate":"2020-05-19","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":300},{"nctId":"NCT06422403","phase":"PHASE2","title":"A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2024-11-25","conditions":"Carcinoma, Hepatocellular, Gastric Adenocarcinoma, GastroEsophageal Cancer","enrollment":360},{"nctId":"NCT02794571","phase":"PHASE1","title":"Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-05-23","conditions":"Advanced/Metastatic Tumors","enrollment":518},{"nctId":"NCT05055908","phase":"PHASE3","title":"Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2021-10-01","conditions":"Lung Cancer","enrollment":12000},{"nctId":"NCT04054908","phase":"","title":"Gut Microbiome in Colorectal Cancer","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2018-04-13","conditions":"Gastrointestinal Microbiome, Neoplasm, Colorectal","enrollment":50},{"nctId":"NCT05717738","phase":"","title":"Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2022-01-20","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":300},{"nctId":"NCT05284539","phase":"PHASE2","title":"Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2022-04-01","conditions":"Non Small Cell Lung Cancer","enrollment":760},{"nctId":"NCT05059951","phase":"","title":"Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2021-10-03","conditions":"Non Small Cell Lung Cancer","enrollment":15000},{"nctId":"NCT06261138","phase":"","title":"Survival Analysis: TACE vs. Combination Therapy in HCC","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2019-02-01","conditions":"Hepatocellular Carcinoma","enrollment":279},{"nctId":"NCT05065021","phase":"PHASE2","title":"Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2023-02-23","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":40},{"nctId":"NCT02386826","phase":"PHASE1","title":"INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2015-09-22","conditions":"Glioblastoma Multiforme, Gliosarcoma, Colorectal Cancer","enrollment":65},{"nctId":"NCT03952403","phase":"PHASE3","title":"A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2019-12-02","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":643},{"nctId":"NCT02039674","phase":"PHASE1, PHASE2","title":"A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-02-21","conditions":"Non-small Cell Lung Carcinoma","enrollment":267},{"nctId":"NCT02336165","phase":"PHASE2","title":"Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma","status":"COMPLETED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2015-02-26","conditions":"Glioblastoma","enrollment":159},{"nctId":"NCT04861948","phase":"PHASE1","title":"IBI188 Combination Therapy in Solid Tumors","status":"TERMINATED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2021-05-25","conditions":"Solid Tumors, Lung Adenocarcinoma, Osteosarcoma","enrollment":9},{"nctId":"NCT01433991","phase":"PHASE1, PHASE2","title":"A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)","status":"TERMINATED","sponsor":"Eisai Inc.","startDate":"2011-10-13","conditions":"Advanced Solid Tumors","enrollment":30},{"nctId":"NCT02661815","phase":"PHASE1","title":"A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2016-06-15","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma","enrollment":6},{"nctId":"NCT01959490","phase":"PHASE2","title":"Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2013-09-24","conditions":"Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer","enrollment":16},{"nctId":"NCT01705002","phase":"PHASE1","title":"Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.","status":"COMPLETED","sponsor":"Lipomedix Pharmaceuticals Inc.","startDate":"2012-10","conditions":"Cancer, Solid Tumor, Metastatic Colorectal Cancer (mCRC)","enrollment":88},{"nctId":"NCT01229644","phase":"PHASE2","title":"Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas","status":"TERMINATED","sponsor":"Arog Pharmaceuticals, Inc.","startDate":"2011-04","conditions":"Glioma","enrollment":10},{"nctId":"NCT01791140","phase":"","title":"BEVERLY-C: An Observational Study of Avastin (Bevacizumab) in First-Line Treatment in Elderly Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-03","conditions":"Colorectal Cancer","enrollment":3},{"nctId":"NCT00809133","phase":"PHASE1","title":"Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-05","conditions":"Neoplasms","enrollment":83},{"nctId":"NCT00953121","phase":"PHASE2","title":"Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)","status":"COMPLETED","sponsor":"Annick Desjardins","startDate":"2009-09","conditions":"Malignant Glioma","enrollment":104},{"nctId":"NCT01055795","phase":"PHASE1","title":"Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors","status":"COMPLETED","sponsor":"Herbert Hurwitz","startDate":"2010-03","conditions":"Advanced Solid Tumors","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Cohort C: bevacizumab","genericName":"Cohort C: bevacizumab","companyName":"PPD Development, LP","companyId":"ppd-development-lp","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A). Used for Metastatic colorectal cancer, Metastatic non-small cell lung cancer, Metastatic renal cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}